QQ客服 官方微博 反馈留言

	Egfr signaling confers resistance to bet inhibition in hepatocellular carcinoma through stabilizing oncogenic myc
	Yin, Yalei1; Sun, Mingju1; Zhan, Xi1,2; Wu, Changqing1; Geng, Pengyu1; Sun, Xiaoyan1,5,6,7,8; Wu, Yunsong1,4; Zhang, Shuijun5,6,7,8; Qin, Jianhua1; Zhuang, Zhengping3
刊名	Journal of experimental & clinical cancer research
	2019-02-15
卷号	38页码:15
关键词	Bromodomain Jq1 Mapk pathway Myc Egfr mutation Sorafenib
ISSN号	1756-9966
DOI	10.1186/s13046-019-1082-6
通讯作者	Liu, yang(yliuqq@dicp.ac.cn)
英文摘要	Backgroundthe bromodomain and extra-terminal domain (bet) inhibitor is a type of anti-tumor agent, currently being evaluated in phase i and ii clinical trials for cancer therapy. it can decrease myc expression levels and cause effective anti-tumor effects in diverse human cancers. however, its cytotoxic effect and related mechanisms of drug resistance are poorly understood in hepatocellular carcinomas (hcc). here, we investigated the anti-tumor effects of bet inhibitor on hcc and the molecular mechanisms involved in its associated drug resistance.methodswe assessed the cytotoxicity of bet inhibitor on hcc cells compared with sorafenib by cell viability assay, metastasis assay and reproduced the anti-tumor effect in xenograft mouse model. in addition, the molecular mechanisms involved in drug resistance on jq1-resistant hcc cells were revealed by western blotting, qrt-pcr, whole exome-sequencing and gene-editing technology. finally, with specific inhibition of egfr or erk activity by interference rnas or inhibitors, the efficacy of the synergistic treatment was investigated using cell viability assay, colony formation, apoptosis and xenograft mouse model.resultswe found that jq1, a commonly used bet bromo-domain inhibitor, offered a better anti-tumor response than sorafenib in myc-positive hcc cells by inducing apoptosis in vitro and in vivo. unlike sorafenib, jq1 treatment significantly impaired mitochondrial respiration and glycolysis in hcc cells. importantly, we revealed that mapk activation by a previously undescribed activating mutation of egfr-i645l, was critical for jq1 sensitivity through stabilizing oncogenic myc protein in jq1-resistant hcc cells. inhibition of either egfr or erk activity overcame the jq1 resistance and significantly decreased myc protein level in vitro and in vivo.conclusionsince myc amplification is frequently identified in hcc, co-occurring with egfr amplification, our findings suggest that targeting egfr signaling might be essential for jq1 therapy in advanced hcc.
WOS关键词	C-MYC ; SORAFENIB ; CELLS ; JQ1 ; AMPLIFICATION ; THERAPY
WOS研究方向	Oncology
WOS类目	Oncology
语种	英语
出版者	BMC
WOS记录号	WOS:000459069300001
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2372754
专题	大连化学物理研究所
通讯作者	Liu, Yang
作者单位	1.Chinese Acad Sci, Dalian Inst Chem Phys, Sci Res Ctr Translat Med, CAS Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China 2.Dalian Univ, Sch Life Sci, Dalian 116023, Peoples R China 3.NINDS, Surg Neurol Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA 4.Wuhan Univ, Coll Chem & Mol Sci, Wuhan 430072, Hubei, Peoples R China 5.Zhengzhou Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China 6.Zhengzhou Univ, Open & Key Lab Hepatobiliary & Pancreat Surg & Di, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China 7.Zhengzhou Key Lab Hepatobiliary & Pancreat Dis &, Zhengzhou, Henan, Peoples R China 8.Henan Key Lab Digest Organ Transplantat, Zhengzhou, Henan, Peoples R China 9.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
推荐引用方式 GB/T 7714	Yin, Yalei,Sun, Mingju,Zhan, Xi,et al. Egfr signaling confers resistance to bet inhibition in hepatocellular carcinoma through stabilizing oncogenic myc[J]. Journal of experimental & clinical cancer research,2019,38:15.
APA	Yin, Yalei.,Sun, Mingju.,Zhan, Xi.,Wu, Changqing.,Geng, Pengyu.,...&Liu, Yang.(2019).Egfr signaling confers resistance to bet inhibition in hepatocellular carcinoma through stabilizing oncogenic myc.Journal of experimental & clinical cancer research,38,15.
MLA	Yin, Yalei,et al."Egfr signaling confers resistance to bet inhibition in hepatocellular carcinoma through stabilizing oncogenic myc".Journal of experimental & clinical cancer research 38(2019):15.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。